EQS — News: invIOs publishes positive clinical data on CBL — B — silenced autologous cell therapy APN401 in peer — reviewed journal

EQS-News: invIOs GmbH / Key word(s): Scientific publication invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal 15.10.2026 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════ invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal • Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors • Decentralized point-of-care manufacturing of APN401 was feasible across manufacturing sites • APN401 demonstrated a favorable safety profile, with no dose-limiting toxicities or grade ≥3 treatment-related adverse events • Disease stabilization was observed in 5 of 10 RECIST-evaluable patients Vienna, Austria, 15 October 2026: invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular